Welcome to our dedicated page for OMNICELL SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Omnicell, Inc. filings document financial results, guidance updates, governance matters, and capital-plan items for a Nasdaq-listed healthcare technology company focused on medication management. Form 8-K reports furnish quarterly and annual operating results and record material events such as executive appointments and amendments to bylaws.
Proxy materials describe annual meeting proposals, director elections, executive compensation votes, equity incentive plan authorization, certificate of incorporation amendments, auditor ratification, and related stockholder voting mechanics. These filings also provide formal disclosure around Omnicell’s common stock governance, board oversight, and stockholder rights provisions.
OMNICELL, INC. (OMCL) reported that officer Brian H. Nutt, VP and Chief Accounting Officer, had 937 shares of common stock withheld on 2026-08-15 at $37.30 per share to cover taxes due on the vesting of restricted stock units. Following this tax-withholding disposition, his direct holdings total 22,265.8924 shares of common stock. The reported balance also reflects 343.2789 shares purchased the same day under Omnicell’s Employee Stock Purchase Plan.
OMNICELL, INC. (OMCL) reported insider activity by President & COO Njoku Nnamdi. On August 17, 2026, he sold 3,083 shares of common stock at $36.85 per share in an open-market transaction effected under a Rule 10b5-1 trading plan adopted on February 9, 2026. On August 15, 2026, 3,670 shares were disposed of at $37.30 per share to cover taxes due upon vesting of restricted stock units, with the reported balance adjusted for 882.119 shares purchased under the company’s Employee Stock Purchase Plan.
OMNICELL, INC. (OMCL) Chairman and CEO Randall A. Lipps reported an automatic withholding of 12,350 shares of Common Stock at $37.30 on August 15, 2026 to cover taxes due upon vesting of restricted stock units. After this tax-withholding disposition and inclusion of 261.6432 shares purchased the same day under the Employee Stock Purchase Plan, he holds 511,095.7173 shares directly. He also reports indirect holdings of 345,861 shares in a trust with his wife and 8,051 shares in a trust for his children.
OMNICELL, INC. (OMCL) reported an insider transaction by executive vice president and chief legal/administrative officer Corey J. Manley. On 2026-08-15, 4,025 shares of common stock were withheld to pay taxes due upon vesting of restricted stock units at a reference price of $37.30 per share. After this tax-withholding disposition and a same-date purchase of 226.4621 shares under the Employee Stock Purchase Plan, Manley directly held 108,984.8013 shares of Omnicell common stock.
Omnicell insider Nnamdi T. Njoku filed a notice of intent to sell 3,083 shares of common stock, with an aggregate market value of $113,608.55, through Fidelity Brokerage Services LLC on August 17, 2026 on NASDAQ. The shares relate to restricted stock vesting scheduled for August 15, 2026 and are categorized as compensation. The notice also reports a prior sale of 3,090 common shares for $133,549.80 on May 18, 2026.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 1,734,375 shares of Omnicell, Inc. common stock, representing 3.8% of the outstanding class. All reported shares are subject to shared voting and dispositive power, with no sole voting or dispositive power.
The filing states that the securities are held by entities over which Millennium Management LLC and related investment managers exercise voting control and investment discretion, and that this should not itself be construed as an admission of beneficial ownership. The group indicates ownership of 5 percent or less of the class and includes a joint filing agreement dated August 7, 2026.
Omnicell, Inc. reported stronger results for the quarter and six months ended June 30, 2026. Second‑quarter total revenue was $312.2 million, up from $290.6 million a year earlier, with growth in both product and service lines. First‑half revenue reached $622.1 million versus $560.2 million in 2025.
Quarterly net income was $24.3 million (diluted EPS $0.52), compared with $5.6 million (EPS $0.12) last year; for the first half, net income was $35.6 million versus a prior‑year loss of $1.4 million. Gross profit increased to $152.9 million in Q2, aided by lower product costs, including a $14.5 million refund of previously paid tariffs recorded primarily as a reduction of cost of product revenues.
Operating cash flow for the first six months rose to $122.8 million from $68.7 million, supporting cash and cash equivalents of $292.2 million at June 30, 2026. Total assets were $2.0 billion, stockholders’ equity $1.29 billion, and the company had $172.5 million principal of 1.00% convertible senior notes due 2029 outstanding, while its $350 million revolving credit facility remained fully available.
Omnicell, Inc. reported strong second quarter 2026 results, with total revenues of $312 million, up $22 million, or 7% from the prior-year quarter. GAAP net income was $24 million, or $0.52 per diluted share, while non-GAAP net income was $44 million, or $0.94 per diluted share. Non-GAAP EBITDA reached $67 million, supported by demand for connected devices, SaaS and services, disciplined costs, and a $15 million refund of previously paid IEEPA tariffs that reduced product costs.
Operating cash flow in the quarter was $68 million, and as of June 30, 2026 Omnicell held $292 million in cash and cash equivalents, against $168 million of total debt and $350 million of undrawn revolver capacity. For 2026, the company guides total revenues to $1.225–$1.245 billion, non-GAAP EBITDA to $175–$185 million, and non-GAAP diluted EPS to $2.15–$2.30. Q3 2026 revenues are projected at $301–$307 million with non-GAAP EPS of $0.35–$0.43. Omnicell also announced the promotion of Nnamdi Njoku to President and Chief Operating Officer and added two senior pharmacy-focused leadership roles.
Randall A. Lipps, chairman and CEO of Omnicell, Inc., reported an indirect sale of 10,000 shares of common stock on July 15, 2026 at $47.00 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
After this transaction, a trust with his wife holds 345,861 shares indirectly, a separate trust for his children holds 8,051 shares indirectly, and he holds 523,184.0741 shares directly.